Clevudine for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Clevudine for COVID-19

1 study with 61 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 Clevudine studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−744%

Viral clearance (1)27%

RCTs (1)−744%

Late (1)−744%

00.511.5+

← Clevudine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Dec 14 2021	Song et al., medRxiv, doi:10.1101/2021.12.09.21267566	Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity
	744% worse recovery (p=0.16) and 27% improved viral clearance (p=0.56). RCT 61 moderate COVID-19 patients in Korea showing no significant difference in viral clearance or clinical outcomes with clevudine compared to placebo.
Jul 8 2021	Song et al., NCT04891302	A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19
	104 patient clevudine late treatment RCT with results not reported over 5 years after completion.